Ratings Chengdu Olymvax Biopharmaceuticals Inc.

Equities

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-05-30 EDT			5-day change	1st Jan Change
9.69 ^CNY	-0.41%		+19.48%	-38.67%

05-16	Olymvax Biopharma's Flu Vaccine Gets China Nod for Clinical Trials	MT
04-25	Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's profit outlook over the next few years is a strong asset.
The company returns high margins, thereby supporting business profitability.
Analysts covering this company mostly recommend stock overweighting or purchase.
Analyst opinion has improved significantly over the past four months.

With an expected P/E ratio at 51 and 26.43 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

	1st Jan change	Capi.	ESG Refinitiv
CHENGDU OLYMVAX BIOPHARMACEUTICALS INC.	-38.67%	543M	-
CSL LIMITED	-1.85%	89.87B	A-
SAMSUNG BIOLOGICS CO.,LTD.	-3.95%	37.57B	A-
BIOGEN INC.	-13.07%	32.75B	B-
UCB	+63.37%	26.47B	A
BIOMARIN PHARMACEUTICAL INC.	-22.14%	14.25B	C
INCYTE CORPORATION	-7.96%	12.99B	B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.33%	11.93B	D+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-46.33%	10.84B	B
SWEDISH ORPHAN BIOVITRUM AB	+5.54%	9.11B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality